Table 1.
Baseline demographic and clinical characteristics of 27 patients with bloodstream infections due to Enterobacteriaceae, treated with piperacillin–tazobactam (TZP). Data are number of patients (percentage), unless otherwise stated. CrCl, creatinine clearance, Sequential Organ Failure Assessment (SOFA), ESBL, extended-spectrum beta-lactamase, MIC,
| Variable | No. of Cases (%) Unless Otherwise Stated |
|---|---|
| Male gender | 17 (62.96) |
| Age in years, median (range) | 76.5 (48–86) |
| Body mass index ≥ 25 | 19 (79.1) |
| CrCl in mL/min, median (range) | 50.7 (45.3–255.3) |
| Charlson score, median (range) | 2.5 (0–8) |
| Comorbidities: | |
| Diabetes mellitus | 13 (48.1) |
| Chronic pulmonary disease | 4 (14.8) |
| Cancer | 11 (40.7) |
| Liver cirrhosis | 1 (3.7) |
| Immunosuppressive therapy | 1 (3.7) |
| Source of bacteremia | |
| Urinary tract | 18 (66.67) |
| Biliary tract | 7 (25.9) |
| Other intraabdominal infection | 2 (7.4) |
| Community-acquired bacteremia | 11 (40.7) |
| Pitt score, median (range) | 2 (0–5) |
| SOFA score at diagnosis, median (range) | 3 (0–8) |
| Microorganism: | |
| Escherichia coli | 15 (55.5) |
| Klebsiella oxytoca | 6 (22.2) |
| Klebsiella pneumoniae | 3 (11.1) |
| Enterobacter aerogenes | 2 (7.4) |
| Enterobacter cloacae | 1 (3.7) |
| ESBL producer | 3 (11.1) |
| Hours from blood culture until first TZP dose, median (range) | 1.6 (0–11) |
| MIC | 25 (92.5) |
| 1 mg/L | 3 (12) |
| 2 mg/L | 13 (52) |
| 4 mg/L | 5 (20) 1 |
| 8 mg/L | 3 (12) 2 |
| 16 mg/L | 0 |
| >16 mg/L | 1 (3.7) |
| Outcome: | |
| Lack of improvement, day 2 | 5 (18.5) |
| Clinical failure, day 14 | 4 (14.8) |
| Mortality, day 30 | 1 (3.7) |
1 2 were ESBL producers. 2 1 was an ESBL producer.